.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Updates in the Treatment of Waldenström Macroglobulinemia

EP. 1: Updates in the Treatment of Waldenström Macroglobulinemia

August 13th 2021

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

EP. 2: Dr. Ailawadhi on Patient Considerations for BTK Inhibitors in Waldenström Macroglobulinemia

September 3rd 2021

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

EP. 3: Dr. Castillo on the Integration of BTK Inhibitors in Waldenström

September 3rd 2021

Jorge J. Castillo, MD, discusses the integration of BTK inhibitors in Waldenström macroglobulinemia.